吉林敖东：控股子公司洮南药业获得小牛脾提取物注射液国家药品标准（修订）颁布件

Core Viewpoint - Jilin Aodong's subsidiary, Taonan Pharmaceutical, has received the revised national drug standard for "Bovine Spleen Extract Injection," which is expected to create favorable conditions for the company's steady development, although sales remain uncertain due to market environment changes [1] Group 1 - The national drug standard revision includes updates on identification, high molecular weight substances, amino acids, osmotic pressure molar concentration, biological activity, bacterial endotoxins, antihypertensive substances, peptides, and ribonucleic acid content measurement [1] - The revised quality standards will be implemented from the date of issuance, ensuring compliance with the new requirements [1] - The company acknowledges that the sales situation of the drug may be influenced by changes in the market environment, indicating potential uncertainties [1]